标题
Value and affordability of CAR T-cell therapy in the United States
作者
关键词
-
出版物
BONE MARROW TRANSPLANTATION
Volume -, Issue -, Pages -
出版商
Springer Science and Business Media LLC
发表日期
2020-05-30
DOI
10.1038/s41409-020-0956-8
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Pivotal Safety and Efficacy Results from Transcend NHL 001, a Multicenter Phase 1 Study of Lisocabtagene Maraleucel (liso-cel) in Relapsed/Refractory (R/R) Large B Cell Lymphomas
- (2020) Jeremy S. Abramson et al. BLOOD
- Mosunetuzumab Induces Complete Remissions in Poor Prognosis Non-Hodgkin Lymphoma Patients, Including Those Who Are Resistant to or Relapsing After Chimeric Antigen Receptor T-Cell (CAR-T) Therapies, and Is Active in Treatment through Multiple Lines
- (2020) Stephen J Schuster et al. BLOOD
- KTE-X19 CAR T-Cell Therapy in Relapsed or Refractory Mantle-Cell Lymphoma
- (2020) Michael Wang et al. NEW ENGLAND JOURNAL OF MEDICINE
- Chimeric Antigen Receptor T Cell Immunotherapy for Tumor: A Review of Patent Literatures
- (2019) Manxue Fu et al. Recent Patents on Anti-Cancer Drug Discovery
- Estimating Long-Term Survival for Patients with Relapsed or Refractory Large B-cell Lymphoma Treated with Chimeric Antigen Receptor Therapy: A Comparison of Standard and Mixture Cure Models
- (2019) Aasthaa Bansal et al. MEDICAL DECISION MAKING
- Factors associated with durable EFS in adult B-cell ALL patients achieving MRD-negative CR after CD19 CAR-T cells
- (2019) Kevin A. Hay et al. BLOOD
- Evolution of CAR T-cell immunotherapy in terms of patenting activity
- (2019) Björn Jürgens et al. NATURE BIOTECHNOLOGY
- A safe and potent anti-CD19 CAR T cell therapy
- (2019) Zhitao Ying et al. NATURE MEDICINE
- Anti-BCMA CAR T-Cell Therapy bb2121 in Relapsed or Refractory Multiple Myeloma
- (2019) Noopur Raje et al. NEW ENGLAND JOURNAL OF MEDICINE
- Cost Effectiveness of Chimeric Antigen Receptor T-Cell Therapy in Multiply Relapsed or Refractory Adult Large B-Cell Lymphoma
- (2019) John K. Lin et al. JOURNAL OF CLINICAL ONCOLOGY
- Cost Effectiveness of Blinatumomab Versus Inotuzumab Ozogamicin in Adult Patients with Relapsed or Refractory B-Cell Precursor Acute Lymphoblastic Leukemia in the United States
- (2019) Thomas E. Delea et al. PHARMACOECONOMICS
- Competition and price among brand-name drugs in the same class: A systematic review of the evidence
- (2019) Ameet Sarpatwari et al. PLOS MEDICINE
- Medical crowdfunding to access CAR T-cell therapy
- (2019) Linda D Ho et al. LANCET ONCOLOGY
- Patient-Reported Neuropsychiatric Outcomes of Long-Term Survivors after Chimeric Antigen Receptor T Cell Therapy
- (2019) Julia Ruark et al. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION
- Affordability Boards — The States’ New Fix for Drug Pricing
- (2019) Tara Sklar et al. NEW ENGLAND JOURNAL OF MEDICINE
- Advancing Legislation on Drug Pricing — Is There a Path Forward?
- (2019) Stacie B. Dusetzina et al. NEW ENGLAND JOURNAL OF MEDICINE
- Comparative Approaches to Drug Pricing
- (2019) So-Yeon Kang et al. Annual Review of Public Health
- Machine learning to predict 30-day quality-adjusted survival in critically ill patients with cancer
- (2019) Hellen Geremias dos Santos et al. JOURNAL OF CRITICAL CARE
- Engineering strategies to overcome the current roadblocks in CAR T cell therapy
- (2019) Sarwish Rafiq et al. Nature Reviews Clinical Oncology
- The financial burden and distress of patients with cancer: Understanding and stepping-up action on the financial toxicity of cancer treatment
- (2018) Pricivel M. Carrera et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Alternative payment and care-delivery models in oncology: A systematic review
- (2018) Emeline M. Aviki et al. CANCER
- Financial Hardship and the Economic Effect of Childhood Cancer Survivorship
- (2018) Paul C. Nathan et al. JOURNAL OF CLINICAL ONCOLOGY
- PiggyBac-Engineered T Cells Expressing CD19-Specific CARs that Lack IgG1 Fc Spacers Have Potent Activity against B-ALL Xenografts
- (2018) David C. Bishop et al. MOLECULAR THERAPY
- Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic Leukemia
- (2018) Shannon L. Maude et al. NEW ENGLAND JOURNAL OF MEDICINE
- Resolving the “Cost-Effective but Unaffordable” Paradox: Estimating the Health Opportunity Costs of Nonmarginal Budget Impacts
- (2018) James Lomas et al. VALUE IN HEALTH
- Financial burden among older, long-term cancer survivors: Results from the LILAC study
- (2018) Theresa A. Hastert et al. Cancer Medicine
- Detection of Replication Competent Lentivirus Using a qPCR Assay for VSV-G
- (2018) Lindsey M. Skrdlant et al. Molecular Therapy-Methods & Clinical Development
- Total Costs of Chimeric Antigen Receptor T-Cell Immunotherapy
- (2018) Inmaculada Hernandez et al. JAMA Oncology
- Cost Effectiveness of Chimeric Antigen Receptor T-Cell Therapy in Relapsed or Refractory Pediatric B-Cell Acute Lymphoblastic Leukemia
- (2018) John K. Lin et al. JOURNAL OF CLINICAL ONCOLOGY
- National Coverage Analysis of CAR-T Therapies — Policy, Evidence, and Payment
- (2018) Peter B. Bach NEW ENGLAND JOURNAL OF MEDICINE
- Cost evolution of biological agents for the treatment of spondyloarthritis in a tertiary hospital: influential factors in price
- (2018) Mariángeles González-Fernández et al. International Journal of Clinical Pharmacy
- Cost-effectiveness of axicabtagene ciloleucel for adult patients with relapsed or refractory large B-Cell lymphoma in the United States
- (2018) Joshua A. Roth et al. JOURNAL OF MEDICAL ECONOMICS
- ASBMT Consensus Grading for Cytokine Release Syndrome and Neurological Toxicity Associated with Immune Effector Cells
- (2018) Daniel W Lee et al. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION
- Why Biologics and Biosimilars Remain So Expensive: Despite Two Wins for Biosimilars, the Supreme Court’s Recent Rulings do not Solve Fundamental Barriers to Competition
- (2018) Brian K. Chen et al. DRUGS
- Cost-Effectiveness of Chimeric Antigen Receptor T-Cell Therapy in Pediatric Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia
- (2018) Reith R Sarkar et al. JNCI-Journal of the National Cancer Institute
- Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1–2 trial
- (2018) Frederick L Locke et al. LANCET ONCOLOGY
- Tisagenlecleucel in Adult Relapsed or Refractory Diffuse Large B-Cell Lymphoma
- (2018) Stephen J. Schuster et al. NEW ENGLAND JOURNAL OF MEDICINE
- PCN72 - BUDGET IMPACT ANALYSIS OF TISAGENLECLEUCEL FOR THE TREATMENT OF ADULT PATIENTS WITH RELAPSED OR REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA IN ENGLAND
- (2018) S. Hollmann et al. VALUE IN HEALTH
- Characterization of clinical grade CD19 chimeric antigen receptor T cells produced using automated CliniMACS prodigy system
- (2018) Wei Zhang et al. Drug Design Development and Therapy
- Long-term Survival and Value of Chimeric Antigen Receptor T-Cell Therapy for Pediatric Patients With Relapsed or Refractory Leukemia
- (2018) Melanie D. Whittington et al. JAMA Pediatrics
- Accounting for All Costs in the Total Cost of Chimeric Antigen Receptor T-Cell Immunotherapy
- (2018) Melanie D. Whittington et al. JAMA Oncology
- Development of a Novel Anti-CD19 Chimeric Antigen Receptor: A Paradigm for an Affordable CAR T Cell Production at Academic Institutions
- (2018) Maria Castella et al. Molecular Therapy-Methods & Clinical Development
- Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma
- (2017) Sattva S. Neelapu et al. NEW ENGLAND JOURNAL OF MEDICINE
- Blinatumomab versus Chemotherapy for Advanced Acute Lymphoblastic Leukemia
- (2017) Hagop Kantarjian et al. NEW ENGLAND JOURNAL OF MEDICINE
- Global Manufacturing of CAR T Cell Therapy
- (2017) Bruce L. Levine et al. Molecular Therapy-Methods & Clinical Development
- Cost–effectiveness thresholds: pros and cons
- (2016) Melanie Y Bertram et al. BULLETIN OF THE WORLD HEALTH ORGANIZATION
- Recommendations for Conduct, Methodological Practices, and Reporting of Cost-effectiveness Analyses
- (2016) Gillian D. Sanders et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Enhanced CAR T-cell engineering using non-viral Sleeping Beauty transposition from minicircle vectors
- (2016) R Monjezi et al. LEUKEMIA
- The Ethics and Economics of Pharmaceutical Pricing
- (2015) Sara Parker-Lue et al. Annual Review of Pharmacology and Toxicology
- Low-cost generation of Good Manufacturing Practice–grade CD19-specific chimeric antigen receptor–expressing T cells using piggyBac gene transfer and patient-derived materials
- (2015) Saumya Ramanayake et al. CYTOTHERAPY
- Minimum Costs for Producing Hepatitis C Direct-Acting Antivirals for Use in Large-Scale Treatment Access Programs in Developing Countries
- (2014) A. Hill et al. CLINICAL INFECTIOUS DISEASES
- Updating Cost-Effectiveness — The Curious Resilience of the $50,000-per-QALY Threshold
- (2014) Peter J. Neumann et al. NEW ENGLAND JOURNAL OF MEDICINE
- Financing cures in the United States
- (2014) Anirban Basu Expert Review of Pharmacoeconomics & Outcomes Research
- Changing Physician Incentives for Affordable, Quality Cancer Care: Results of an Episode Payment Model
- (2014) Lee N. Newcomer et al. Journal of Oncology Practice
- Health outcomes in economic evaluation: the QALY and utilities
- (2010) S. J. Whitehead et al. BRITISH MEDICAL BULLETIN
- What Is Value in Health Care?
- (2010) Michael E. Porter NEW ENGLAND JOURNAL OF MEDICINE
Find the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
SearchBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started